Press Releases

Cesca Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

RANCHO CORDOVA, Calif., Oct. 24, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on Tuesday October 29, at 12:45 pm ET. Management will … Continued

Cesca Therapeutics Forms Joint Venture with HealthBanks Biotech (USA) to Provide Immune Cell Banking and Cell Processing Services

ImmuneCyte to Begin Operations in Fourth Quarter of 2019   RANCHO CORDOVA, Calif., Oct. 21, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture … Continued

Cesca Therapeutics to Present at the 2019 BIO Investor Forum

RANCHO CORDOVA, Calif., October 14, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the 2019 BIO Investor Forum on Tuesday, October 22 at 4:00 pm PT. The … Continued

Cesca Therapeutics Announces Receipt of $2 Million Upfront Distribution Fee

RANCHO CORDOVA, Calif., October 2, 2019 – Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), announced today it has received the $2 million upfront distribution fee pursuant to its global distribution agreement, entered into as … Continued

ThermoGenesis Reports Performance Evaluations of X-Series® Cell Processing Devices

RANCHO CORDOVA, Calif., Sept. 25, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), today reported Validations of System Performance for their X-Series® products from two prestigious academic medical centers:  Marcus Center for … Continued

Cesca Therapeutics And ThermoGenesis Announce Major Global Distribution Agreement For The Company’s X-Series® Products

RANCHO CORDOVA, Calif., Sept. 9, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), filed a Form 8-K last Friday with the Securities and Exchange Commission announcing the signing of an exclusive, global … Continued

Cesca Therapeutics To Present At The H.C. Wainwright 21st Annual Global Investment Conference

RANCHO CORDOVA, Calif., Sept. 3, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10 at 12:30 … Continued

Cesca Therapeutics Announces Improved Second Quarter 2019 Financial Results and Provides Corporate Update

Revenue Grows by 115% and the Company Records Positive Adjusted EBITDA  for the Second Quarter of 2019 Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT RANCHO CORDOVA, Calif., Aug. 13, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, … Continued

Cesca Therapeutics To Announce Financial Results For The Second Quarter Ended June 30, 2019 And Host A Conference Call On August 13

RANCHO CORDOVA, Calif., Aug. 6, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that the Company will release its financial results for the second quarter ended June 30, 2019 on Tuesday, August 13, 2019 after the close of trading.  A conference call … Continued

America’s Largest Cord Blood Bank, CBR®, Upgrading to ThermoGenesis’ AXP® II System

RANCHO CORDOVA, Calif., July 23, 2019 /PRNewswire/ — ThermoGenesis, a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL) and a market leader in automated cellular processing, today announced that CBR® (Cord Blood Registry), the country’s largest newborn stem cell storage bank has begun the process to transition to ThermoGenesis’ next-generation AXP® II System for the rapid … Continued

© 2020 ThermoGenesis Corp.
How may we help?